Show simple item record

dc.contributor.authorPerera, FPen_US
dc.contributor.authorMooney, LAen_US
dc.contributor.authorStampfer, Men_US
dc.contributor.authorPhillips, DHen_US
dc.contributor.authorBell, DAen_US
dc.contributor.authorRundle, Aen_US
dc.contributor.authorCho, Sen_US
dc.contributor.authorTsai, WYen_US
dc.contributor.authorMa, Jen_US
dc.contributor.authorBlackwood, Aen_US
dc.contributor.authorTang, DLen_US
dc.date.accessioned2018-09-17T15:18:12Z
dc.date.issued2002-10en_US
dc.identifier10en_US
dc.identifier.citationCARCINOGENESIS, 2002, 23 pp. 1641 - 1646en_US
dc.identifier.issn0143-3334en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2749
dc.identifier.doi10.1093/carcin/23.10.1641en_US
dc.description.abstractDNA damage from polycyclic aromatic hydrocarbons (PAH) and other aromatic/hydrophobic compounds has been implicated in case-control studies as a risk factor for lung cancer, as have common polymorphisms in the glutathione S-transferase (GST) genes involved in carcinogen detoxification. However, their joint effects have not been evaluated in prospective studies, leaving open questions about predictive value of these biomarkers. In this matched case-control study nested within the prospective Physicians’ Health Study, we evaluated whether biomarkers measured in white blood cells (WBC) significantly predicted risk, alone and in combination, after controlling for level of smoking. The biomarkers reported here are aromatic/hydrophobic-DNA adducts and polymorphisms in genes coding for the GSTM1 and GSTP1 enzymes. Our study population was composed of 89 cases of primary lung cancer and 173 controls, matched in a 1:2 ratio on smoking, age and duration of follow up. Adducts were measured in WBC DNA by the nuclease P1-enhanced P-32-post-labeling method. Genotypes (GSTM1 null versus non-null and GSTP1 Val versus GSTP Ile) were determined by genomic amplification and restriction fragment length polymorphism analysis. Among current smokers, adducts were significant predictors of lung cancer risk (after adjusting for GST genotypes, OR = 3.10, 95% CI 1.07, 9.01). The combined GSTM1 null/GSTP1 Val genotype was associated with lung cancer overall and especially among former smokers, before and after adjusting for adducts (OR for former smokers = 4.21, CI 1.08, 16.41; adjusted OR = 4.68, CI 1.17, 18.71). Among cases only, adducts were significantly higher among current or former smokers with the GSTM1 non-null/GSTP1 Ile genotype. The two risk factors (adducts and genotypes) appear to be independent predictors of risk. The findings underscore the complex and important role of biological susceptibility as a determinant of risk from carcinogens found in tobacco smoke and other environmental compounds.en_US
dc.format.extent1641 - 1646en_US
dc.titleAssociations between carcinogen-DNA damage, glutathione S-transferase genotypes, and risk of lung cancer in the prospective Physicians’ Health Cohort Studyen_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1093/carcin/23.10.1641en_US
rioxxterms.licenseref.startdate2002-10en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfCARCINOGENESISen_US
pubs.notesresearcherid-numbers: Rundle, Andrew/A-5282-2009 orcid-numbers: Rundle, Andrew/0000-0003-0211-7707 Mooney, LaVerne A./0000-0003-1120-356X unique-id: ISI:000178801800011en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Human Biomonitoring & Carcinogen Activation
pubs.volume23en_US
pubs.embargo.termsNot knownen_US
icr.researchteamHuman Biomonitoring & Carcinogen Activationen_US
dc.contributor.icrauthorPhillips, David Hunteren_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record